DK171746B1 - Transdermalt afgivelsessystem - Google Patents

Transdermalt afgivelsessystem Download PDF

Info

Publication number
DK171746B1
DK171746B1 DK316788A DK316788A DK171746B1 DK 171746 B1 DK171746 B1 DK 171746B1 DK 316788 A DK316788 A DK 316788A DK 316788 A DK316788 A DK 316788A DK 171746 B1 DK171746 B1 DK 171746B1
Authority
DK
Denmark
Prior art keywords
alkyl
enantiomer
delivery system
transdermal delivery
amino
Prior art date
Application number
DK316788A
Other languages
Danish (da)
English (en)
Other versions
DK316788A (da
DK316788D0 (da
Inventor
John Michael Pawelchak
James Ronald Lawter
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of DK316788D0 publication Critical patent/DK316788D0/da
Publication of DK316788A publication Critical patent/DK316788A/da
Application granted granted Critical
Publication of DK171746B1 publication Critical patent/DK171746B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
DK316788A 1987-06-12 1988-06-10 Transdermalt afgivelsessystem DK171746B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6184287A 1987-06-12 1987-06-12
US6184287 1987-06-12

Publications (3)

Publication Number Publication Date
DK316788D0 DK316788D0 (da) 1988-06-10
DK316788A DK316788A (da) 1988-12-13
DK171746B1 true DK171746B1 (da) 1997-05-05

Family

ID=22038497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK316788A DK171746B1 (da) 1987-06-12 1988-06-10 Transdermalt afgivelsessystem

Country Status (16)

Country Link
EP (1) EP0294601B1 (ko)
JP (1) JP2654092B2 (ko)
KR (1) KR970000506B1 (ko)
AT (1) ATE84714T1 (ko)
AU (1) AU609142B2 (ko)
CA (1) CA1305418C (ko)
DE (1) DE3877630T2 (ko)
DK (1) DK171746B1 (ko)
ES (1) ES2043719T3 (ko)
GR (1) GR3006938T3 (ko)
IE (1) IE62735B1 (ko)
IL (1) IL86334A (ko)
NO (1) NO178096C (ko)
NZ (1) NZ224891A (ko)
PT (1) PT87704B (ko)
ZA (1) ZA884186B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US6075024A (en) * 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
US5476854A (en) * 1991-11-27 1995-12-19 Sepracor Inc. Methods and compositions for treating bacterial infection using optically pure (R)-lomefloxacin
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
DE69333009T2 (de) * 1992-11-09 2003-12-04 Neurogesx, Inc. Transdermale verabreichung von ketorolac
NZ530227A (en) 2001-06-18 2006-09-29 Noven Pharma Enhanced drug delivery in transdermal systems
CN100444840C (zh) 2003-05-15 2008-12-24 罗斯坎普研究有限公司 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物
EP2214666B1 (en) 2007-10-05 2013-12-11 Alzheimer's Institute of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
US4284634A (en) * 1975-07-02 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, and pharmaceutical method of the same
CA1117117A (en) * 1978-10-10 1982-01-26 Fujisawa Pharmaceutical Co., Ltd. 2-methyl-dihydropyridine compound, processes for preparation thereof and pharmaceutical composition comprising the same
JPS6016917A (ja) * 1983-07-08 1985-01-28 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンまたはニフエジピンの軟膏剤
JPS60258179A (ja) * 1984-06-04 1985-12-20 Yamanouchi Pharmaceut Co Ltd Ｙｍ−０９７３０のジアステレオマ−ａの右旋性光学異性体またはその酸付加塩，該化合物の製造方法および該化合物からなる医薬
DE3419128A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinpraeparate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
NO882559D0 (no) 1988-06-10
NO178096B (no) 1995-10-16
IE881749L (en) 1988-12-12
ES2043719T3 (es) 1994-01-01
AU1761088A (en) 1988-12-15
KR970000506B1 (ko) 1997-01-13
JP2654092B2 (ja) 1997-09-17
PT87704A (pt) 1988-07-01
DK316788A (da) 1988-12-13
JPS6413024A (en) 1989-01-17
PT87704B (pt) 1993-03-31
IL86334A (en) 1992-09-06
DK316788D0 (da) 1988-06-10
NO882559L (no) 1988-12-13
EP0294601A3 (en) 1989-10-11
CA1305418C (en) 1992-07-21
ZA884186B (en) 1989-03-29
EP0294601B1 (en) 1993-01-20
EP0294601A2 (en) 1988-12-14
AU609142B2 (en) 1991-04-26
DE3877630T2 (de) 1993-06-03
IE62735B1 (en) 1995-02-22
ATE84714T1 (de) 1993-02-15
NZ224891A (en) 1992-06-25
GR3006938T3 (ko) 1993-06-30
DE3877630D1 (de) 1993-03-04
NO178096C (no) 1996-01-24
KR890000090A (ko) 1989-03-11

Similar Documents

Publication Publication Date Title
US5114946A (en) Transdermal delivery of pharmaceuticals
US4992445A (en) Transdermal delivery of pharmaceuticals
US5001139A (en) Enchancers for the transdermal flux of nivadipine
US11872214B2 (en) Formulations of Bendamustine
DK171746B1 (da) Transdermalt afgivelsessystem
BR112016015911B1 (pt) Composição farmacêutica contendo composto do ácido piridilaminoacético e óleo de rícino polioxietilenado e método para a estabilização de (6-{[4- (pirazol-1- il)benzil](piridin-3- ilsulfonil)aminometil} piridin-2- ilamino) acetato de isopropila ou um sal do mesmo
JP2006111614A (ja) 安定化された注射用水溶液製剤
US4071620A (en) Stabilization of oxygen sensitive dose forms
KR900014396A (ko) 티에노-트리아졸로-디아제핀 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
AR040077A1 (es) Composiciones farmaceuticas y metodos de uso de derivados de epotilona modificados por c-21
KR100525058B1 (ko) 광안정성을 높인 수성 약제학적 조성물 및 광안정화 방법
JPH06700B2 (ja) 安定な水性液剤

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired